[HTML][HTML] mRNA-based therapeutics—developing a new class of drugs
In vitro transcribed (IVT) mRNA has recently come into focus as a potential new drug class to
deliver genetic information. Such synthetic mRNA can be engineered to transiently express …
deliver genetic information. Such synthetic mRNA can be engineered to transiently express …
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across
AK Minnaert, H Vanluchene, R Verbeke… - Advanced drug delivery …, 2021 - Elsevier
The recent approval of messenger RNA (mRNA)-based vaccines to combat the SARS-CoV-
2 pandemic highlights the potential of both conventional mRNA and self-amplifying mRNA …
2 pandemic highlights the potential of both conventional mRNA and self-amplifying mRNA …
The mRNA Vaccine Revolution: COVID-19 has launched the future of Vaccinology
During the COVID-19 pandemic, mRNA (mRNA) vaccines emerged as leading vaccine
candidates in a record time. Nonreplicating mRNA (NRM) and self-amplifying mRNA (SAM) …
candidates in a record time. Nonreplicating mRNA (NRM) and self-amplifying mRNA (SAM) …
Engineered nucleic acids encoding a modified erythropoietin and their expression
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
[HTML][HTML] mRNA therapeutics in cancer immunotherapy
JD Beck, D Reidenbach, N Salomon, U Sahin… - Molecular cancer, 2021 - Springer
Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment
or peptide and lends itself to a broad range of pharmaceutical applications, including …
or peptide and lends itself to a broad range of pharmaceutical applications, including …
Terminally modified RNA
T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
[HTML][HTML] How mRNA therapeutics are entering the monoclonal antibody field
L Van Hoecke, K Roose - Journal of Translational Medicine, 2019 - Springer
In 1975, Milstein and Köhler revolutionized the medical world with the development of the
hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies …
hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies …
[HTML][HTML] mRNA-based cancer vaccines: a therapeutic strategy for the treatment of melanoma patients
M Bidram, Y Zhao, NG Shebardina, AV Baldin… - Vaccines, 2021 - mdpi.com
Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of
death from skin tumors. Given the increased incidence of melanoma diagnoses in recent …
death from skin tumors. Given the increased incidence of melanoma diagnoses in recent …
Engineered nucleic acids and methods of use thereof
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C (= O) C (NC (= O)
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
Modified polynucleotides for the production of biologics and proteins associated with human disease
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …